# INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Source: https://onco.cc/trials/nct03491683/  
OnCo record `nct03491683` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of INO-5401, Cemiplimab and Temozolomide in glioma & glioblastoma, run by Inovio Pharmaceuticals, active and no longer recruiting.

## Summary

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) is a phase 1/2 interventional study registered as NCT03491683 by Inovio Pharmaceuticals, with 52 participants enrolled, started 2018-05-31 and due to reach its primary completion in 2026-12-31. Interventions recorded: INO-5401, INO-9012, Cemiplimab, Radiation Therapy and Temozolomide.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03491683
- Phase: 1/2
- Setting: An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
- Sponsor: Inovio Pharmaceuticals
- Enrolled: 52

## Sources

- ClinicalTrials.gov NCT03491683: https://clinicaltrials.gov/study/NCT03491683

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [Cemiplimab](https://onco.cc/drugs/cemiplimab/), [INO-5401](https://onco.cc/drugs/ino-5401/), [Temozolomide](https://onco.cc/drugs/temozolomide/)
- companies: [Inovio Pharmaceuticals](https://onco.cc/companies/inovio/)

---
JSON: https://onco.cc/api/v1/entities/nct03491683.json